Why Myeloid Precursors Are Tested
Myeloid precursors are tested primarily to diagnose and classify myeloid neoplasms (particularly myelodysplastic syndromes and acute myeloid leukemia), assess disease progression, detect minimal residual disease, and distinguish malignant cells from normal regenerating bone marrow.
Diagnostic and Classification Purposes
For Myelodysplastic Syndromes (MDS)
Myeloid precursor assessment is essential for MDS diagnosis when morphologic findings alone are inconclusive. When 3 or more phenotypic abnormalities are found involving one or more myeloid lineages by flow cytometry, the findings can be considered indicative of MDS 1. This is particularly important because:
- Dysplasia in ≥10% of cells in one or more myeloid lineages is required for diagnosis
- The percentage of blasts in bone marrow directly determines MDS subclassification (e.g., RAEB-1 has 5-9% blasts, RAEB-2 has 10-19% blasts)
- Flow cytometry can detect asynchronous expression of maturation-associated antigens on myeloid cells, though this alone is "suggestive" rather than diagnostic without morphologic confirmation 1
For Acute Myeloid Leukemia (AML)
AML diagnosis requires ≥20% myeloid blasts out of 500 bone marrow cells, including myeloblasts, monoblasts/promonocytes, and megakaryoblasts 2. Myeloid precursor testing enables:
- Differentiation of AML from MDS
- Identification of specific AML subtypes based on genetic abnormalities
- Distinction of AML with myelodysplasia-related changes (MRC-AML), which requires ≥50% dysplastic cells in at least two cell lineages 2
Detection of Minimal Residual Disease (MRD)
A critical pitfall exists here: regenerating bone marrow after chemotherapy shows substantial expansion of myeloid precursors (CD34+ cells) that can reach up to 12% of bone marrow cells 3. This creates diagnostic challenges:
- In regenerating marrow, myeloid precursors increase significantly (mean 1.27% in B-ALL patients post-induction vs. 0.38% in controls)
- These normal regenerating precursors express CD45 (95%), CD117 (38%), CD38 (91%), HLA-DR (91%), CD13 (73%), and CD33 (85%)
- Accurate interpretation is critical to avoid misdiagnosing normal regeneration as relapse or secondary leukemia 3
Three distinct subsets of normal myeloid precursors exist in regenerating marrow: CD34+ CD117- HLA-DR+, CD34+ CD117+ HLA-DR+, and CD34- CD117+ HLA-DR-/+ without aberrant marker expression 3.
Disease Progression Monitoring
From Precursor States to MDS
Myeloid precursor testing tracks progression from:
- ICUS (idiopathic cytopenia of undetermined significance) → CCUS (clonal cytopenia) → MDS
- Lower-risk MDS → higher-risk MDS → AML
Bcl-2 expression by myeloid precursors correlates with MDS stage and progression: early MDS shows 9.9% bcl-2+ early myeloid precursors versus 26.4% in advanced MDS, increasing to 57% when evolving to AML 4. This reflects accumulation of immature myeloid cells with decreased apoptosis.
Practical Testing Algorithm
At diagnosis, obtain:
- Bone marrow aspirate for cytology with Sudan Black B, myeloperoxidase, and esterase staining
- Immunophenotyping by multiparameter flow cytometry (minimum 4-color)
- Bone marrow biopsy (mandatory if dry-tap)
- Cytogenetic analysis for recurrent abnormalities
- Molecular testing for mutations (NPM1, CEBPA, TP53, etc.)
For inconclusive morphology with unilineage dysplasia:
- If no recurrent cytogenetic abnormality, no blast increase, and <15% ring sideroblasts: observe for 6 months with repeat bone marrow investigation before diagnosing MDS 1
- This ensures features persist and aren't secondary to nutritional deficiencies, medications, toxins, or infections
During treatment monitoring:
- Recognize that myeloid precursors normally expand during regeneration
- Compare phenotypic patterns to established normal regenerating marrow profiles
- Look for aberrant antigen expression patterns that deviate from the three normal regenerating subsets 3